Juniper Pharmaceuticals Reports Third Quarter 2017 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St slips as climbing oil, yields amplify inflation fears
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- CoreWeave stock drops on dilution fears and debt concerns
Juniper Pharma (JNP) Tops Q3 EPS by 4c
November 2, 2017 5:09 PM EDTJuniper Pharma (NASDAQ: JNP) reported Q3 EPS of ($0.13), $0.04 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $13 million versus the consensus estimate of $12.55 million.
For earnings history and earnings-related data on Juniper Pharma (JNP) click here.
... More


